Elevance Health, Inc.
No SEC Form 4 filings for $ELV in the last 30 days.
See all $ELV insider activity →Elevance Health announced new transparency policies to prevent providers from charging hospital rates for off-campus services, aiming to reduce patient costs. This follows a Blue Cross Blue Shield study showing $411 million in extra out-of-pocket costs for patients. The policy could save significant costs if adopted system-wide, according to the company.
Elevance Health (ELV) is expected to report Q3 2026 earnings on October 21, with analysts forecasting $4.69 EPS and $49.16B revenue. Estimates have declined 7.5% over 90 days, signaling concerns. The company faces year-over-year declines in both earnings and revenue. Investors will focus on medical loss ratios, membership trends, and guidance.
Elevance Health (ELV) introduced new billing policies to distinguish between hospital and off-campus care, aiming to reduce patient costs and slow premium growth. The insurer will pay lower rates for services delivered outside hospitals, potentially saving patients hundreds of dollars. Hospitals argue this could limit care access, while lawmakers propose broader site-neutral payment reforms, with estimates suggesting $150B in Medicare savings over a decade.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ELV (Elevance Health, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 1 bearish.
Recent ELV coverage spans financial news, regulation and market movers.
Policy may improve cost perception and reduce pricing complaints, offering modest upside.
Earnings preview suggests potential downside pressure if results miss consensus.
Policy change could pressure hospital reimbursement economics and shift insurer-provider billing dynamics, with potential downstream effects on utilization and premium growth.
Analyst upgrade suggests upside potential for ELV.
The stars downgrade may pressure ELV shares despite a 15% pre‑market rally.
AlphAI scores every news story that mentions ELV with an AI model for sentiment and relevance, and aggregates insider trades from Elevance Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elevance Health announced new transparency policies to prevent providers from charging hospital rates for off-campus services, aiming to reduce patient costs. This follows a Blue Cross Blue Shield study showing $411 million in extra out-of-pocket costs for patients. The policy could save significant costs if adopted system-wide, according to the company.
3 min readElevance Health (ELV) is expected to report Q3 2026 earnings on October 21, with analysts forecasting $4.69 EPS and $49.16B revenue. Estimates have declined 7.5% over 90 days, signaling concerns. The company faces year-over-year declines in both earnings and revenue. Investors will focus on medical loss ratios, membership trends, and guidance.
2 min readElevance Health (ELV) introduced new billing policies to distinguish between hospital and off-campus care, aiming to reduce patient costs and slow premium growth. The insurer will pay lower rates for services delivered outside hospitals, potentially saving patients hundreds of dollars. Hospitals argue this could limit care access, while lawmakers propose broader site-neutral payment reforms, with estimates suggesting $150B in Medicare savings over a decade.
7 min readGuggenheim raised its price target on Elevance Health (NYSE:ELV) to $460 from $455, citing improved performance in Medicaid, Medicare Advantage, and ACA segments. The firm expects continued earnings growth and maintains a Buy rating. Elevance reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share. Other analysts have mixed views on the stock.
2 min readCantor Fitzgerald maintained an Overweight rating and $450 price target for Elevance Health (ELV) despite a decline in its 2027 Medicare Stars ratings. The firm expects pressure on the stock due to concerns around Medicare Advantage management. Elevance reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share. Analysts have mixed views, with Guggenheim raising its target to $455 and RBC lowering it to $424.
2 min readElevance Health Inc. saw improved prospects after the release of Medicare Advantage star ratings on Oct. 8. Humana's shares rose 13% in after-hours trading, while other managed care organization shares showed less volatility.
1 min readNutex Health (NUTX) and Elevance Health (ELV) have outperformed the healthcare sector in 2026, with NUTX up 36% and ELV up 11%. NUTX trades at a P/E of 9, while ELV is at 18, both below the sector average of 29.75. NUTX reported strong earnings growth, and ELV reaffirmed its 2026 guidance, highlighting stabilization in its cost structure.
2 min readVice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.
2 min readElevance Health (ELV) will stop paying hospital rates for certain off-campus clinic care, instead using lower off-campus rates. The policy, rolling out in 2026-2027, aims to reduce facility fees and make healthcare more affordable. Elevance cited a 2023 analysis showing Medicare paid $2.7B more for services in hospital outpatient settings. The move follows state and federal actions on billing transparency.
2 min readJefferies reports Medicaid enrollment attrition rose to 0.5% in August 2026, exceeding the 2026 monthly average of 0.3%. Humana showed flat enrollment, while other MCOs like Centene, Elevance Health, Molina, and UnitedHealth are expected to report lower Q3 attrition. State policy changes contributed to enrollment churn, with Jefferies noting a morbidity shift due to disenrollment.
1 min read
